Management of major recurrent aphthous ulcers with 5% amlexanox oral paste and rebamipide tablets- A case report with a brief literature review

---

Case Report

Author Details : Shamimul Hasan*, Mohd. Faisal Siddique

Volume : 8, Issue : 4, Year : 2023

Article Page : 225-229

https://doi.org/10.18231/j.ijpi.2023.043

Suggest article by email

Get Permission

---

Abstract

Recurrent aphthous stomatitis (RAS) is a common chronic inflammatory oral mucosal disorder marked by the presence of painful, recurring ulcers, occurring either as solitary lesions or in multiple clusters. While the clinical features of this condition are easily recognizable, the precise etiology remains obscure. The disorder manifests in three forms, of which minor RAS are the commonest and heal within 10-14 days. Major RAS presents as larger, painful chronic ulcerations and heals with scarring in 6-8 weeks. A comprehensive medical history and a thorough systemic examination can aid the physician in determining whether the condition is idiopathic or linked to a underlying systemic disorder. The management of oral aphthous ulcers poses a significant challenge and there is no established and defined therapeutic regimen available for RAS. We present a case of major RAS in a 37-year-old patient who was unresponsive to topical and systemic steroid therapy. 5% Amlexenox paste and rebamipide tablets were used in the present case. The patient showed favourable healing within a week therapy with no recurrences during the 6-month follow up.

Keywords: Amlexanox, Rebamipide, Recurrent aphthous stomatitis, Major aphthaous, Corticosteroids

How to cite : Hasan S, Siddique M F, Management of major recurrent aphthous ulcers with 5% amlexanox oral paste and rebamipide tablets- A case report with a brief literature review. IP Int J Periodontol Implantol 2023;8(4):225-229

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.